IART

AI Memo

Integra LifeSciences

As of 2026-09-09/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-09 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Planned fourth-quarter SurgiMend relaunch • 2026-12-08

Base target: $20 / p=50% prob

Biggest risk

Revenue growth remains modest, Tissue Reconstruction declined 2.0% organically, ENT declined 1.9% with reimbursement pressure, and the post-print context reports roughly a 1.6% share-price decline plus downward estimate-review momentum. Execution slippage on the relaunch or continued wound-reconstruction weakness would challenge the thesis.

Invalidation

Break below $14 or thesis failure.

What would change my mind?

The Q2 print showed adjusted EPS of $0.56 versus $0.45 a year earlier, adjusted EBITDA margin expansion to 18.7%, improving supply reliability, and a planned SurgiMend relaunch. These support a cautious recovery case, but the stored consensus-beat and revision evidence is secondary and analyst coverage is incomplete.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-09

Base target

$20

p=50%

Bull target

$22

p=25%

Bear target

$14

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Supply reliability and margin execution
Delivery of reaffirmed 2026 outlook
The Q2 print showed adjusted EPS of $0.56 versus $0.45 a year earlier, adjusted EBITDA margin expansion to 18.7%, improving supply reliability, and a planned SurgiMend relaunch.

BearKey bullets

2026 reported revenue guidance was updated for stronger U.S.
dollar effects, while underlying organic growth guidance remains low.
[#SEC-8K-2026-07-29]

WatchKey bullets

Planned fourth-quarter SurgiMend relaunch

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $20 (p=50%)

Target spread vs base: +12% / -31%

Scenario probabilities

Bull Target: $22 (p=25%)Base Target: $20 (p=50%)Bear Target: $14 (p=25%)

Commentary

The post-earnings tone is mixed: operating metrics and guidance were constructive, but growth is low, tissue reconstruction remains weak, and stored Zacks context reports a roughly 1.6% decline since the print alongside downward estimate reviews. Social, options, short-interest, and employee-sentiment data are unavailable, so sentiment is mainly filing and earnings driven.

As of 2026-09-09 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Supply reliability and margin execution
Delivery of reaffirmed 2026 outlook

Scenarios

Bull Target (Scenario probability)

$22 / p=25% prob

Base Target (Scenario probability)

$20 / p=50% prob

Bear Target (Scenario probability)

$14 / p=25% prob

Analysis 2026-09-09 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.10

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-08
Planned fourth-quarter SurgiMend relaunch
Braintree production has begun and management remains on track for a planned fourth-quarter SurgiMend relaunch, creating a concrete execution milestone. [#SEC-8K-2026-07-29]
Prob 60.00% • Move 12.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Supply reliability and margin execution
2026-12-08
Q2 adjusted EBITDA margin expanded to 18.7%, while management cited improving supply reliability, lower remediation spending, and margin initiatives. [#SEC-8K-2026-07-29]
Prob 55% • Move 6% • Priced-in 45%

Long-term Catalysts

Months to a year

Delivery of reaffirmed 2026 outlook
2027-09-09
Management reaffirmed 2026 organic revenue growth guidance of 0.8%-3.3% and adjusted EPS guidance of $2.40-$2.50, leaving upside if portfolio execution improves without renewed supply or reimbursement pressure. [#SEC-8K-2026-07-29]
Prob 50% • Move 15% • Priced-in 40%

Risks

2026 reported revenue guidance was updated for stronger U.S. dollar effects, while underlying organic growth guidance remains low. [#SEC-8K-2026-07-29]
Analyst target count, rating changes, and detailed post-earnings estimate revisions are not available in the packet, limiting confidence in the valuation signal.
ENT sales declined 1.9% organically and management cited continuing reimbursement pressure on sinus balloons. [#SEC-8K-2026-07-29]
The planned fourth-quarter SurgiMend relaunch remains an execution milestone; delays or quality and supply setbacks could weaken the recovery case. [#SEC-8K-2026-07-29]
Tissue Reconstruction remains under pressure, with Q2 organic revenue down 2.0%. [#SEC-8K-2026-07-29]

Peers

Symbol	Summary
ENOV	Closer-size medtech comparator for execution and margin benchmarking, though product mix differs.
AORT	Closer-size medical-device comparator with more relevant scale context than large-cap peers, but business exposure is not identical.
ABT	Large diversified medtech scale comparator; useful for sector context but not a tight operating peer.
BSX	Large-cap device comparator with materially different scale and growth profile; broad sector reference only.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-09

Loading AI feed…

Symbol

Summary

ENOV

Closer-size medtech comparator for execution and margin benchmarking, though product mix differs.

AORT

Closer-size medical-device comparator with more relevant scale context than large-cap peers, but business exposure is not identical.

ABT

Large diversified medtech scale comparator; useful for sector context but not a tight operating peer.

BSX

Large-cap device comparator with materially different scale and growth profile; broad sector reference only.